Association between ex vivo pharmacotyping of patient-derived tumor organoids and personalized therapeutic options for patients with biliary tract cancer.
Payel Chatterjee(Precision for Medicine (United States)), Carla Grandori(Precision for Medicine (United States)), Milind Javle(The University of Texas MD Anderson Cancer Center), Alex Rajewski(Precision for Medicine (United States)), Gentry Teng King(University of Washington), Rachele Rosati(Precision for Medicine (United States)), Brady Bernard(Providence Portland Medical Center), Christopher J. Kemp(Fred Hutch Cancer Center), William Proctor Harris(University of Washington), Annie Richardson, Robert L. Diaz, Adam Diehl(University of Washington), Shalini Pereira(Precision for Medicine (United States)), Lauren Appleyard(Precision for Medicine (United States))
Cited by 1
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903